Stay updated with breaking news from Analyst Day. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Treatment with setrusumab for at least 6 months resulted in 67% reduction in annualized fracture rate in patients with OI in Phase 2/3 Orbit study Quantitative data from the Phase 1/2 study of...
Fears about the economy and bond yields mask a rare opportunity fueled by artificial intelligence.
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous and meaningful improvements in bone mineral density...
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate...
Public filing of a Form 10 registration statement with the U.S. SEC in connection with the planned separation of Worthington Steel....